mifepristone also known medication typically used combination misoprostol bring medical abortion pregnancy manage early combination effective first days also effective second trimester taken common adverse effects include abdominal pain feeling tired vaginal serious side effects may include heavy vaginal bleeding bacterial infection birth defects pregnancy used appropriate followup care needs mifepristone works blocking effects progesterone making cervix uterine vessels dilate causing uterine mifepristone developed came use france became available united states world health organizations list essential mifepristone approved canada january mifepristone followed prostaglandin analog misoprostol gemeprost used medical medical organizations found combination safe effective guidelines royal college obstetricians gynaecologists describe medication abortion using mifepristone misoprostol effective appropriate gestational world health organization american college obstetricians gynecologists recommend mifepristone followed misoprostol first secondtrimester medical mifepristone alone less effective resulting abortion within weeks anywhere pregnancies according review mifepristone used medical treatment high blood sugar caused high cortisol levels blood hypercortisolism adults endogenous cushings syndrome also type diabetes mellitus glucose intolerance failed surgery phase iii trial improved glycemic control increased insulin sensitivity reduced body weight regardless cause mifepristone low doses used emergency may also used together misoprostol early pregnancy mifepristone also used treat symptomatic leiomyoma uterine fibroids serious complications mifepristone rare requiring hospitalization requiring blood nearly women using mifepristonemisoprostol regimen experienced abdominal pain uterine cramping vaginal bleeding spotting average days women severe cramps use misoprostol last less hours generally managed women experienced type bleeding days less common side effects included nausea vomiting diarrhea dizziness fatigue pelvic inflammatory disease rare serious excessive bleeding incomplete termination pregnancy require intervention doctor repeat dose misoprostol vacuum aspiration mifepristone contraindicated presence adrenal failure longterm oral corticosteroid therapy although inhaled topical steroids fine hemorrhagic disorders inherited porphyria hemophilia anticoagulant women intrauterine device uterus remove iud prior medication abortion avoid unnecessary cramping mifepristone effective treating ectopic pregnancy postmarketing summary found million women received mifepristone april united states reported died application eight cases associated sepsis six various causes drug abuse suspected murder incidents reported fda included nonlethal hospitalizations blood transfusions severe infections adverse events longterm studies evaluate carcinogenic potential mifepristone performed accord ich guidelines require carcinogenicity testing nongenotoxic drugs intended administration less six mifepristone alone results abortion within weeks effectiveness increases greater misoprostol given evidence effects mifepristone although antiabortion groups claim reversed giving researchers united states initiated trial socalled reversal regimen stopped prematurely due serious safety concerns using mifepristone without followup giving progesterone shown halt medication abortion completing combination regimen mifepristone misoprostol may cause serious continue pregnancy use mifepristone together misoprostol termination birth defects may exposure single large dose mifepristone newborn rats associated reproductive problems although chronic lowdose exposure newborn rats mifepristone associated structural functional reproductive studies mice rats rabbits revealed developmental abnormalities rabbits rats mifepristone steroidal antiprogestogen nm pr well antiglucocorticoid nm gr antiandrogen nm ar much lesser antagonizes cortisol action competitively receptor presence progesterone mifepristone acts competitive progesterone receptor antagonist absence progesterone mifepristone acts partial agonist mifepristone steroid bulky pdimethylamino phenyl substituent plane molecule responsible inducing stabilizing inactive receptor conformation hydrophobic substituent plane molecule increases progesterone receptor binding addition antiprogestogen mifepristone also antiglucocorticoid weak antiandrogen mifepristones relative binding affinity progesterone receptor twice progesterone relative binding affinity glucocorticoid receptor three times dexamethasone ten times relative binding affinity androgen receptor less onethird testosterone bind estrogen receptor mineralocorticoid mifepristone regular contraceptive mg daily prevents ovulation mg daily single preovulatory dose mifepristone delays ovulation three four days effective emergency contraceptive single dose progestin women mifepristone doses greater equal mgkg antagonizes endometrial myometrial effects progesterone humans antiglucocorticoid effect mifepristone manifested doses greater equal mgkg compensatory increase acth cortisol animals weak antiandrogenic effect seen prolonged administration high doses medication abortion regimens mifepristone blockade progesterone receptors directly causes endometrial decidual degeneration cervical softening dilatation release endogenous prostaglandins increase sensitivity myometrium contractile effects prostaglandins mifepristoneinduced decidual breakdown indirectly leads trophoblast detachment resulting decreased syncytiotrophoblast production hcg turn causes decreased production progesterone corpus luteum pregnancy dependent progesterone production corpus luteum first nine weeks placental progesterone production increased enough take place corpus luteum progesterone production followed sequentially prostaglandin mifepristone mg mg may mg effective mg producing medical contragestion term promoted étienneémile baulieu context advocacy mifepristone defining inclusive hypothesized mechanisms action contraceptives mifepristone induce baulieus definition contragestive included birth control method could possibly act fertilization nineweeks gestational elimination halflife complex according label distribution phase elimination first slow concentration decreasing half hours rapid giving elimination halflife hours radio receptor assay techniques terminal halflife hours including metabolites mifepristone able bind progesterone metapristone major metabolite mifepristone also known synthetic estrane steroid derivative steroid hormones like progesterone cortisol substitutions positions double bonds april part formal research project french pharmaceutical company rousseluclaf development glucocorticoid receptor antagonists endocrinologist étienneémile chemist georges teutsch synthesized mifepristone compound synthesized rousseluclaf shortened discovered also progesterone receptor october étienneémile baulieu consultant rousseluclaf arranged tests use medical abortion women switzerland gynecologist walter herrmann university genevas cantonal hospital successful results announced april october following worldwide clinical trials women mifepristone prostaglandin analogue initially sulprostone gemeprost later misoprostol medical abortion rousseluclaf sought approval france use medical abortion approval announced september october response antiabortion protests concerns majority owner hoechst ag germany rousseluclafs executives board directors voted stop distribution mifepristone announced october two days later french government ordered rousseluclaf distribute mifepristone interests public french health minister claude évin explained could permit abortion debate deprive women product represents medical progress moment government approval drug granted became moral property women property drug following use women france april february mifepristone distributed free charge rousseluclaf began selling mifegyne mifepristone hospitals france february price negotiated french government equivalent per mifegyne subsequently approved great britain july sweden september retirement april hoechst ag chairman wolfgang hilger devout roman blocked expansion may rousseluclaf announced donating without remuneration rights medical uses mifepristone united states population subsequently licensed mifepristone danco laboratories new singleproduct company immune antiabortion boycotts received approval us food drug administration fda mifeprex september april buying remaining rousseluclaf stock early hoechst ag equivalent billion annual revenue announced end manufacture sale mifegyne equivalent million annual revenue transfer rights medical uses mifepristone outside united states exelgyn sa new singleproduct company immune antiabortion boycotts whose ceo former rousseluclaf ceo édouard exelgyn approval mifegyne additional countries countries following first generic form mifepristone united states became available manufactured mifepristone world health organizations list essential since included core list misoprostol special note permitted national law culturally cost availability limit access many parts medication abortions voluntarily reported us centers disease control prevention cdc increased percentage total abortions every year since approval mifepristone less weeks guttmacher institute survey abortion providers estimated medication abortions accounted abortions slightly abortions weeks gestation united states nonhospital medication abortions used mifepristone misoprostol used methotrexate medication abortions accounted first trimester abortions planned parenthood clinics united states considering abortions performed nonhospital facilities medication abortions accounted facilities provided relatively small number abortions fewer procedures per year likely perform medication abortions accounted us abortions france percentage medication abortions abortions continues increase vs england wales early abortions less weeks gestation medicationbased percentage abortions medicationbased increased every year past years doubled last five scotland early abortions medicationbased medication abortion introduced percentage abortions medicationbased increased every year past years sweden early abortions abortions end week gestation medicationbased abortions great britain sweden mifepristone licensed use vaginal gemeprost oral misoprostol women europe medication abortions using mifepristone denmark mifepristone used abortions mifepristone approved abortion united states fda september legal available states washington dc guam puerto prescription drug initially available public pharmacies distribution primarily restricted specially qualified licensed physicians sold danco laboratories brand name mifeprex september states drug could provided licensed physician states prescribing clinician required physically room patient taking roussel uclaf seek us approval united states legal availability initially united states banned importation mifepristone personal use decision supported roussel uclaf roussel uclaf gave us drug rights population council exchange immunity product liability population council sponsored clinical trials united drug went approvable status production intended begin danco group withdrew briefly due corrupt business partner delaying availability us food drug administration fda approved mifepristone end pregnancy days gestation days less since first day womans last menstrual period approved dosing regimen mg mifepristone taken mouth swallowed hours taking mifepristone mcg micrograms misoprostol taken buccally cheek pouch location appropriate mifepristone tablets marketing authorization united states treatment high blood sugar caused high cortisol levels blood hypercortisolism adults endogenous cushings syndrome type diabetes mellitus glucose intolerance failed surgery due pandemic safe access mifepristone concern american college obstetricians gynecologists among groups filed lawsuit relax fdas rule allow mifepristone acquired mailorder retail pharmacies fourth circuit granted preliminary injunction allow distribution supreme court united states issued stay order january retain fdas rule pending results ongoing december fda voluntarily adopted new rule permanently relaxing requirement pill obtained person allowing sent mail prescription still required doctor screen risk factors would make taking pill unsafe january fda relaxed rules allowing retail pharmacy become certified fill mifepristone regulations abortion early pregnancy ruled constitutional decision dobbs v jackson womens health organization states enacted restrictions abortions abortion pills january united states department justice issued interpretation comstock act legal united states postal service employees deliver pills state could know whether pills would used abortion january genbiopro filed suit overturn state laws prohibit sale mifepristone claiming laws invalid federally approved argument state laws seeking ban restrict use mifepristone conflict fdas decision make drug available supported number supreme court decisions including opinions traditionally conservative march wyoming became first us state ban april alliance hippocratic medicine v us food drug administration lawsuit federal district judge matthew j kacsmaryk issued preliminary injunction suspending approval mifepristone would take effect week fifth circuit reversed parts kacsmaryks injunction placed temporary injunction rems change mifepristone appeal supreme court court stayed injunctions april justices samuel alito clarence thomas stating dissent stay allowed mifepristone remain legally available lower courts consider merits case also april lawsuit brought us states district columbia federal district judge thomas rice issued temporary injunction fda reduce access mifepristone states drugs approved fda subsection h two subparts first sets forth ways rush experimental drugs aggressive hiv cancer treatments market speedy approval deemed vital health potential patients second part subsection h applies drugs must meet restrictions use due safety requirements also required meet postmarketing surveillance establish safety results shown clinical trials seconded use much wider population december mifepristone approved second part subsection h result women could pick drug pharmacy required receive directly doctor due possibility adverse reactions excessive bleeding may require blood transfusion incomplete abortion may require surgical intervention drug considered safe physician capable administering blood transfusion surgical abortion available patient event approval mifepristone subsection h included black box warning outside united states mifepristone marketed distributed exelgyn laboratories brand name mifegyne approved use france initial marketing united kingdom sweden austria belgium denmark finland germany greece luxembourg netherlands spain switzerland approved norway russia ukraine serbia montenegro approved belarus latvia estonia moldova albania hungary portugal romania bulgaria czech republic slovenia italy clinical trials constrained protocols requiring women hospitalized three days drug finally approved july officialized later year despite strong opposition vatican italy pill must prescribed used clinical structure sold approved hungary released market yet target mifepristone licensed ireland use abortions weeks since legalised mifepristone available poland abortion highly mifepristone mg tablets mifegyne mifepristone linepharma medabon marketing authorizations european economic area european medicines agency ema mifepristone banned australia private members bill introduced australian senate lift ban transfer power approval therapeutic goods administration tga move caused much debate australian media among politicians bill passed senate february mifepristone legal australia provided regularly several specialized abortion clinics per mifepristone mg tablets marketing authorizations australia tga early first trimester medication abortion followed prostaglandin analog misoprostol days gestational second trimester medication abortion followed prostaglandin new zealand proabortion rights doctors established import company istar submitted request approval medsafe new zealand pharmaceutical regulatory agency court case brought right life new zealand failed use mifepristone mifepristone approved israel clinical trials mifepristone china began october china became first country world approve mifepristone chinese organizations tried purchase mifepristone roussel uclaf refused sell china began domestic production mifepristone cost medication abortion mifepristone higher surgical abortion percentage medication abortions varied greatly ranging cities almost nonexistent rural report united states embassy beijing said mifepristone widely used chinese cities two years according press reports black market developed many women starting buy illegally without prescription private clinics drugstores equivalent causing chinese authorities worry medical complications use without physician mifepristone approved vietnam included mifepristone national reproductive health program mifepristone approved one subsaharan african africa approved also approved one north african also mifepristone approved use india medication abortion referred medical termination pregnancy available medical supervision prescription due adverse reactions excessive bleeding criminal penalties given buying selling black market overthecounter medication induced abortion used available canada limited basis using methotrexate misoprostol clinical trials done various canadian cities comparing methotrexate mifepristone approbation federal government drugs overall similar results mifepristone found act health canada gave approval mifepristone july initially use limited seven weeks pregnancy changed nine weeks previous requirement written consent woman also ended time dispensed directly patient pharmacist prescribing health professional women required ultrasound ensure pregnancy mifepristone registered use azerbaijan georgia uzbekistan guyana moldova mongolia armenia low dose mifepristone tablets emergency contraception available directly pharmacist without prescription prescription low dose mifepristone tablets emergency contraception available prescription armenia gynepriston russia agesta gynepriston mifepristone negele ukraine gynepriston vietnam mifestad ciel many antiabortion groups united states actively campaigned approval continue actively campaign cite either ethical issues abortion safety concerns regarding drug adverse reactions associated religious antiabortion groups outside united states also protested mifepristone especially original target research group discovery development compounds antiglucocorticoid antiglucocorticoid properties great interest treatment severe mood disorders psychosis although review published articles inconclusive efficacy considered use drugs mood disorders proof concept use mifepristone cervical ripening agent medication studied antiandrogen treatment prostate mifepristone showed detectable antihiv activity clinical mifepristone showed initial promise psychotic major depression difficulttotreat form phaseiii clinical trial terminated early due lack studied bipolar post traumatic stress anorexia adj capable preventing gestation either preventing implantation causing uterine lining shed implantation contragestive drug agent also contragestant abortion pill substance called mifepristone developed dr etienne baulieu rousseluclaf company contragestive blocks progesterone receptors endometrium uterine lining preventing buildup progesterone hence uterus sustain pregnancy prevent fertilization implantation technically abortifacient rather contraceptivehttpsenwikipediaorgwikimifepristone